Aussie drink-driving laws have similar penalties, but our BAC level is still at .05. This will be moved to .02 in the coming years.
Be safe for you, your family and the person you may injure because, you thought you were ‘ok to drive!’
SHOULD YOU BE DRIVING? DON'T DRINK AND DRIVE....EVER!
TEST YOURSELF NOW
Those were the words of Minister of Health Ginette Taylor in November 2017, spoken as the government of Canada began to put together Bill 45, known as The Cannabis Act. Over a year has passed since the enactment of Bill 45 and questions still remain regarding the safety of legal cannabis to our pregnant population, both in the short- and long-term. Even preceding the legalization of cannabis in Canada, a 2017 survey by the Centre for Addiction and Mental Health (CAMH) indicated that from 1996–2017, adults of reproductive age (i.e., 18–29 years) in Ontario reported the biggest increase in cannabis use, from 18.3% to 39.1%.3 Moreover, in 2017, the proportion of Ontarians reporting cannabis use in a span of just 1 year rose from 15.7% to 19.4%, representing a total of 2 million people. These trends in usage are of great concern, especially when considering that over the last decade, cannabis use has progressively increased in pregnant women, along with the perception that it poses no risk in perinatal life. Aside from the brain, activation of cannabinoid receptors by Δ9-THC or CBD in peripheral tissues (e.g., pancreas, heart, adipose, and liver) during pregnancy could also directly influence the development of those organs, and consequentially, their function in postnatal life. In addition, Δ9-THC in pregnancy may have indirect effects on long-term non-communicable diseases given that it impedes fetal growth, which is a strong predictor of metabolic disease risk in human offspring.
FOR RELEASE: September 10, 2019
As part of its regular monitoring of health-related advertising claims, the Federal Trade Commission today sent warning letters to three companies that sell oils, tinctures, capsules, “gummies,” and creams containing cannabidiol (CBD), a chemical compound derived from the cannabis plant. The letters warn the companies, which the FTC is not identifying publicly, that it is illegal to advertise that a product can prevent, treat, or cure human disease without competent and reliable scientific evidence to support such claims.
In the letters, the FTC urges the companies to review all claims made for their products, including consumer testimonials, to ensure they are supported by competent and reliable scientific evidence. The letters also warn that selling CBD products without such substantiation could violate the FTC Act and may result in legal action that could result in an injunction and an order to return money to consumers.
E-cigarettes may damage the heart! Scientists ask Public Health England to stop recommending vaping - 90 per cent of studies which had no conflict of interest showed impact on the heart! Asked whether PHE should now change its advice, Martin McKee, Professor of European Public Health…who co-authored the new analysis said: “The simple answer is yes.”